Definium reports Phase 3 hit for LSD drug in severe form of depression

Definium Therapeutics said its LSD candidate significantly improved depression symptoms in a Phase 3 study in major depressive disorder (MDD), with data exceeding analyst expectations. The biotech’s drug, known as DT120, improved patients’ depression score ...